| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka |
Ni-HIGH, UMIN000034222: A phase Ib study of Nivolumab plus Trastuzumab with S-1/Capecitabine plus Oxaliplatin for HER2 positive advanced gastric cancer |
|
|
| Active, not recruiting | 1b | 45 | Japan | Opdivo (nivolumab) - Ono Pharma, BMS, capecitabine - Generic mfg., oxaliplatin - Generic mfg., Herceptin (trastuzumab) - Roche | The Cancer Institute Hospital of JFCR, Ono Pharmaceutical Co., Ltd. | HER2 positive advanced or unresectable gastric cancer | | | | |
ChiCTR-ONC-13004449: Clinical results and side-effects observation of esophageal squamous cell carcinomas treated with preoperative concurrent chemoradiotherapy based on cisplatin associated with tegafur gimeracil oteracil potassium capsule |
|
|
| Recruiting | 1 | 40 | | cisplatin and S1 | Department of Radiation Oncology, Xijing Hospital, the Fourth Military Medical University.; Xi Jing hospital, NSFC | esophageal squamous cell carcinomas | | | | |
NCT03252808: Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients With Unresectable Pancreatic Cancer. |
|
|
| Active, not recruiting | 1 | 36 | Japan | TBI-1401(HF10), HF10, canerpaturev, Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, TS-1, Tegafur-gimeracil-oteracil potassium | Takara Bio Inc. | Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV | 02/20 | 03/35 | | |
ChiCTR-OIN-17011333: Clinical research of S-1 alone and S-1 plus gemcitabine for patients with advanced pancreatic cancer |
|
|
| Not yet recruiting | 1 | 50 | | S-1 ;S-1 combined with gemcitabine | The Affiliated Hospital of Inner Mongolia Medical University; The Affiliated Hospital of Inner Mongolia Medical University, self-financing | pancreatic cancer | | | | |
ChiCTR1900027833: Gemcitabine/nab-paclitaxel/S-1 triple regimen for patients with locally advanced or advanced pancreatic cancer: A prospective, single-arm, phase I study |
|
|
| Recruiting | 1 | 15 | | Initially treated patients with locally advanced or advanced pancreatic cancer will receive gemcitabine, nab-paclitaxel, and S-1 triple therapy chemotherapeutic regimen. | West China Hospital, Sichuan University; West China Hospital, Sichuan University, No | pancreatic cancer | | | | |
NCT03977220: Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric Cancer |
|
|
| Not yet recruiting | 1 | 20 | NA | Nab-paclitaxel combined with S-1 | Shanghai Zhongshan Hospital | Gastric Cancer | 12/21 | 12/23 | | |
NCT05396326: A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer |
|
|
| Not yet recruiting | 1 | 20 | NA | Oxaliplatin, Teysuno, Transarterial arterial chemoinfusion and embolism (TACiE) | Shanghai Zhongshan Hospital | Gastric Cancer | 12/22 | 12/25 | | |
GAS, NCT06229496: Dose Escalation and Dose Expansion Study of in Subjects With Metastatic Pancreatic Adenocarcinoma |
|
|
| Recruiting | 1 | 70 | RoW | Gemcitabine 800mg/m2 + Nab-paclitaxel 100mg/m2 + S-1 (dose according to BSA), Gemcitabine 800mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA), Gemcitabine 1000mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA) | Chang Gung Memorial Hospital | Metastatic Pancreatic Adenocarcinoma | 07/26 | 07/26 | | |
ChiCTR2400082912: A prospective real-world study of conversion therapy alone for gastric cancer patients with liver metastasis |
|
|
| Not yet recruiting | 1 | 35 | | Platinum + fluorouracil regimen (taking S-1 plus oxaliplatin (SOX) regimen as an example) : S-1 40-60mg BID d1-14,q3; PD-1 inhibitor regimen (take tislelizumab as an example) : 200mg, q3w, is recommended based on RATIONALE 305, and moderate adjustment can be made based on patient tolerance; for patients with HER-2 amplification status (HER2+,ISH+/HER3+), trastuzumab was added: a loading dose of 8 mg/kg iv drip for 90 min was recommended; The maintenance dose was 6 mg/kg iv drip for 30-90 min, q3w. If the treatment is delayed or interrupted, the delay time is less than 1 week, the maintenance dose can be used directly. If the delay time was more than 1 week, the loading dose should be reintroduced | The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, The use of tislelizumab for therapy was funded by Beijing BeiGene Ltd | Gastric cancer | | | | |
NCT05867121: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 120 | Europe, Japan, US, RoW | RO7496353, SOF 10, Atezolizumab, RO554126 7; Tecentriq, Capecitabine, S-1, Tegafur/Gimeracil/Oteracil potassium, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine | Genentech, Inc., Chugai Pharmaceutical Co. | Metastatic Solid Tumor, Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma | 12/25 | 12/25 | | |
ChiCTR2400084760: A prospective, single-center clinical study on the efficacy and safety of neoadjuvant treatment with adebrelimab combined with apatinib and chemotherapy in patients with resectable gastric or gastroesophageal junction adenocarcinoma. |
|
|
| Not yet recruiting | 1 | 32 | | Adebrelimab 1200 mg per dose on day 1 (D1), administered via intravenous infusion every three weeks (Q3W); when combined with chemotherapy, adebrelimab should be administered first, followed by chemotherapy after an interval of at least 30 minutes.Tegafur-gimeracil-oteracil (S-1) 40-60 mg twice daily (bid) on days 1-14 (d1-14); Oxaliplatin 130 mg/m2 on day 1 (d1); Apatinib 250 mg orally (po), once daily (qd). | Xijing Hospital, Air Force Medical University; Xijing Hospital, Air Force Medical University, Corporate sponsorship | gastric | | | | |
